PADI4 and rheumatoid arthritis: Most pertinently, significant efforts are currently underway to develop PADI4 inhibitors for the treatment of rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, thrombosis, sepsis, irritable bowel syndrome, and colon cancer (Lewis and Nacht, 2016).